The relationship between pan-immune-inflammation value and survival outcomes in patients with metastatic renal cell carcinoma treated with nivolumab in the second line and beyond: a Turkish oncology group kidney cancer consortium (TKCC) study

Arslan, Cagatay; Yekeduz, Emre; Tural, Deniz; Erturk, Ismail; Karakaya, Serdar; EROL, CİHAN; Ercelep, Ozlem; Sever, Ozlem Nuray; ÜRÜN, YÜKSEL; Karadurmus, Nuri; ŞENDUR, MEHMET ALİ NAHİT; Oksuzoglu, Berna; Can, Orcun; Kucukarda, Ahmet; Senturk Oztas, Nihan; KILIÇKAP, SAADETTİN

Author

Arslan, Cagatay

Yekeduz, Emre

Tural, Deniz

Erturk, Ismail

Karakaya, Serdar

EROL, CİHAN

Ercelep, Ozlem

Sever, Ozlem Nuray

ÜRÜN, YÜKSEL

Karadurmus, Nuri

ŞENDUR, MEHMET ALİ NAHİT

Oksuzoglu, Berna

Can, Orcun

Kucukarda, Ahmet

Senturk Oztas, Nihan

KILIÇKAP, SAADETTİN

Metadata

Show full item record

Abstract

Background Pan-immune-inflammation value (PIV) is an easily accessible immune marker based on peripheral blood to estimate prognosis in patients with cancer. This study evaluates the prognostic value of PIV in patients with metastatic renal cell carcinoma (mRCC) treated with nivolumab.

URI

http://hdl.handle.net/20.500.12627/184183
https://avesis.istanbul.edu.tr/api/publication/aba155b8-6686-4b3a-81fb-c3b41fa0ab10/file
https://doi.org/10.1007/s00432-022-04055-5

Collections

Makale [2276]